NANOTEC and GPO to upgrade drug innovation in Thailand

Published: 5-Jul-2011
Media Research & Development

To support projected growth of pharma market in the region

Thailand’s National Nanotechnology Centre (NANOTEC) and the Government Pharmaceutical Organisation (GPO) have signed a strategic research collaboration agreement to focus on drug discovery using nanotechnology.

The partnership will help upgrade the research capabilities of the two Thai agencies and promote national competitiveness, said Soontorn Vorakul, acting managing director for the GPO.

‘The focus of the research collaboration will be in the area of cosmeceutical and drug delivery using nanotechnology,’ he said.

Professor Sirirurg Songsivilai, executive director of NANOTEC, added that the opportunities for nanotechnology in pharmaceutical manufacturing and development are enormous.

‘It is clear that the international pharmaceutical industry has embraced nanotechnology research in their manufacturing. It is essential for the GPO and NANOTEC to join forces and share expertise if we are to keep pace with drug discovery,’ he said.

Thailand will be the eighth largest economy in the Asia Pacific region by 2016, according to the Economist Intelligence Unit (EIU). GDP growth is projected to increase to 7.1% in the same period.

The EIU also projects an annual growth rate of around 0.7% and the population to be the ninth largest in the Asia Pacific region in five years’ time. The elderly population is also rising; Thailand is expected to have the eighth highest proportion in the Asia Pacific region by 2016.

By 2016 it is estimated that Thailand will have the seventh largest pharmaceutical market in the Asia Pacific region.

See more

You may also like

Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

Read more
This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs

Trending Articles

  1. Destination Russia for new NYK Logistics warehouse <p>Logistics specialist NYK is expanding its market presence with the launch of new warehousing operation in Moscow, Russia.</p>
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Landmark NHS‑Galleri trial cuts Stage IV cancers and boosts early detection across England NHS‑Galleri trial shows multi‑cancer blood test sharply reduces late‑stage diagnoses and boosts early detection—possibly signalling a structural change in cancer drug demand, supply chain planning and long-term oncology production strategy
  3. Johnson & Johnson files FDA application for IMAAVY in wAIHA Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
  4. Horizon Europe 2025 grant backs Phase II trial of HER-096 for Parkinson’s disease Herantis Pharma has secured selection for €8m in non-dilutive funding under Horizon Europe to advance a Phase II proof-of-concept study of its subcutaneously delivered Parkinson’s therapy candidate HER-096
  5. THX Pharma and Biocodex pair up to advance rare disease research Biocodex has acquired two licences from THX Pharma to develop and commercialise Batten-1 worldwide and TX01 in the US and Canada, with the deal totalling up to $173m

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Research & Development

Almirall advances etherna’s mRNA/LNP therapy LAD116 into IND-enabling studies

Almirall has selected LAD116, developed using etherna's intratumoral mRNA/LNP platform, for IND-enabling studies in non-melanoma skin cancer, marking a key milestone toward GMP manufacturing and Phase I clinical trials
Research & Development

SPARK THE MIDLANDS backs Aston University anti-cancer bone paste collaboration

A collaboration between Aston University and Royal Orthopaedic Hospital NHS Foundation Trust has secured support from SPARK THE MIDLANDS to advance a minimally invasive gallium-doped injectable paste for treating primary and metastatic bone cancer
Subscribe now